Optimization of a Phase 2 Study Design in Chronic Hepatitis B (CHB) Patients Based on Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) from Phase 1 Studies Using Two Prodrugs of a Toll-like Receptor 7 (TLR7) Agonist

Grippo Joseph; Folitar Ilia; de Rooij Jeroen van de Wetering; Passe Sharon; Blue David R.; Rodriguez Ignacio; Fettner Scott H.; Calleja Elizabeth

首页> 外文期刊>Hepatology: Official Journal of the American Association for the Study of Liver Diseases >Optimization of a Phase 2 Study Design in Chronic Hepatitis B (CHB) Patients Based on Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) from Phase 1 Studies Using Two Prodrugs of a Toll-like Receptor 7 (TLR7) Agonist

【24h】

Optimization of a Phase 2 Study Design in Chronic Hepatitis B (CHB) Patients Based on Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) from Phase 1 Studies Using Two Prodrugs of a Toll-like Receptor 7 (TLR7) Agonist

机译：使用Toll样受体7（TLR7）激动剂的两种前药，基于安全，药代动力学（PK）和药效学（PD）的慢性乙型肝炎（CHB）患者慢性乙型肝炎（CHB）患者的第2期研究设计。（TLR7）激动剂

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Hepatology: Official Journal of the American Association for the Study of Liver Diseases》 |2016年第s1期|共1页
作者
Grippo Joseph; Folitar Ilia; de Rooij Jeroen van de Wetering; Passe Sharon; Blue David R.; Rodriguez Ignacio; Fettner Scott H.; Calleja Elizabeth;
展开▼
作者单位

Roche Innovat Ctr New York Clin Pharmacol New York NY USA;

Roche Innovat Ctr Basel Basel Switzerland;

PRA Hlth Sci Groningen Netherlands;

Roche Innovat Ctr New York New York NY USA;

Roche Innovat Ctr New York New York NY USA;

Roche Innovat Ctr New York New York NY USA;

Roche Innovat Ctr New York New York NY USA;

Roche Innovat Ctr New York New York NY USA;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类消化系及腹部疾病;
关键词

相似文献

外文文献
中文文献

1. Optimization of a Phase 2 Study Design in Chronic Hepatitis B (CHB) Patients Based on Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) from Phase 1 Studies Using Two Prodrugs of a Toll-like Receptor 7 (TLR7) Agonist [J] . Grippo Joseph, Folitar Ilia, de Rooij Jeroen van de Wetering, Hepatology: Official Journal of the American Association for the Study of Liver Diseases . 2016,第S1期

机译：使用Toll样受体7（TLR7）激动剂的两种前药，基于安全，药代动力学（PK）和药效学（PD）的慢性乙型肝炎（CHB）患者慢性乙型肝炎（CHB）患者的第2期研究设计。（TLR7）激动剂
2. AZD8186 study 1: Phase I study to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary anti-tumour activity of AZD8186 in patients with advanced castration resistant prostate cancer (CRPC), squamous non-small cell lung cancer, triple negative breast cancer and with PTEN-deficient/mutated or PIK3CB mutated/amplified malignancies, as monotherapy and in combination with vistusertib (AZD2014) or abiraterone acetate [J] . Lillian S., De Bono J., Higano C., European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) . 2016,第Null期

机译：AZD8186研究1：I期研究，评估AZD8186在先进的阉割前列腺癌（CRPC），鳞状非小细胞肺癌患者中AZD8186的安全性，耐受性，药代动力学（PK），药效学（PD）和初步抗肿瘤活性，三重阴性乳腺癌和PTEN缺乏/突变或PIK3CB突变/扩增的恶性肿瘤，作为单药治疗，与Vistusertib（AZD2014）或乙酸酯组合
3. 3040 POSTER Optimal dose for an every 2 week (q2w) cetuximab (C) regimen in patients (pts) with metastatic colorectal cancer (mCRC): a phase I safety, pharmacokinetics (PK) and pharmacodynamics (PD) study of weekly (q1w) and q2w schedules [J] . F.Ciardiello, A.Cervantes, M.Vega-Villegas, European Journal of Cancer Supplements . 2007,第4期

机译：3040 POSTER转移性结直肠癌（mCRC）患者（pts）的西妥昔单抗（C）方案每2周（q2w）的最佳剂量：每周（q1w）的I期安全性，药代动力学（PK）和药效学（PD）研究和q2w时间表
4. Get Moving - the Practice Nurse is Watching You!: A case study of the user-centered design process and testing of a web-based coaching system to stimulate the physical activity of chronically ill patients in primary care [C] . Renee Verwey, Sanne van der Weegen, Marieke Spreeuwenberg, International Conference on eHealth, Telemedicine, and Social Medicine . 2013

机译：搬运 - 练习护士正在看着你！：以用户为中心的设计过程和基于网络的教练系统的测试，以刺激初级保健中慢性病患者的身体活动
5. A phase Ib study of safety and pharmacokinetics of trastuzumab emtansine and pertuzumab in Japanese patients with HER2-positive metastatic breast cancer [D] . NOGUCHI, Emi 2019

机译：Ib期研究曲妥珠单抗氨丹宁和帕妥珠单抗在日本HER2阳性转移性乳腺癌患者中的安全性和药代动力学
6. Safety tolerability pharmacokinetics and pharmacodynamics of a TLR7 agonist prodrug RO6870868 in healthy volunteers [O] . Joseph F. Grippo, Ilia Folitar, Sharon Passe, 2021

机译：TLR7激动剂前药RO6870868在健康志愿者中的安全性耐受性药代动力学和药效学
7. Safety, Pharmacokinetics, and Efficacy of Olorinab, a Peripherally Acting, Highly Selective, Full Agonist of the Cannabinoid Receptor 2, in a Phase 2a Study of Patients With Chronic Abdominal Pain Associated With Crohn’s Disease [O] . Bruce R Yacyshyn, Stephen Hanauer, Preston Klassen, 2020

机译：olorinab的安全性，药代动力学和疗效，大麻素受体2的外周作用，高度选择性，全激动剂，在与克罗恩病相关的慢性腹痛患者的研究中

Optimization of a Phase 2 Study Design in Chronic Hepatitis B (CHB) Patients Based on Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) from Phase 1 Studies Using Two Prodrugs of a Toll-like Receptor 7 (TLR7) Agonist

著录项

相似文献

相关主题

期刊订阅